<DOC>
	<DOCNO>NCT02956200</DOCNO>
	<brief_summary>Proof-of concept clinical trial indicate sphingosine-1-phosphate receptor modulator fingolimod may efficacious attenuate brain inflammation improve clinical outcome patient AIS single therapy beyond 4.5 hour disease onset , combination alteplase within 4.5 hour disease onset . So study investigator try determine whether addition fingolimod , administer within 6 hour onset symptom patient receive alteplase bridge mechanical thrombectomy , improve radiologic clinical outcome .</brief_summary>
	<brief_title>Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy Acute Ischemic Stroke</brief_title>
	<detailed_description>This prospective , randomize , open-label , blind endpoint ( PROBE ) design clinical trial , multiple stroke center China . The total sample size 98 . Patients treated standard alteplase bridge mechanical thrombectomy randomly assign 1:1 ratio receive oral fingolimod standard care . The primary outcome salvage ischemic tissue baseline day 7 . AIS patient proximal cerebral arterial occlusion CT perfusion ( CTP ) treatment , multimodal MRI include diffusion MR perfusion ( MRP ) 24 hour 7 day receive treatment . Clinical outcome assess use National Institutes Health Stroke Scale score ( NIHSS ) baseline , day 1 day 7 modify Rankin Scale ( mRS ) 90 day . Circulating lymphocyte count monitor FACS baseline , day 1 day 7 confirm biological activity fingolimod . Patients age 18 85 anterior circulation AIS eligible alteplase mechanical thrombectomy commence within 6 hour stroke onset enrol present infarct core volume 15-100 mL least 20 % mismatch ( evaluated CTP ) intracranial occlusion proximal cerebral artery . Exclusion criterion ( 1 ) standard contraindication alteplase mechanical thrombectomy ; ( 2 ) evidence disease CNS ; ( 3 ) pre-existing neurologic disability ( score great 2 mRS ) ; ( 4 ) swallowing difficulty would prevent administration oral fingolimod ; ( 5 ) patient history bradyarrhythmia , atrioventricular block current use beta-blockers verapamil ; ( 6 ) concomitant use antineoplastic , immunosuppressive immune modulate therapy ; ( 7 ) macular edema . As standard care , patient receive standard dose intravenous alteplase ( 0.9 mg per kilogram , first 10 % administered initial bolus remainder 1-hour period , maximum dose 90 mg ) mechanical thrombectomy deliver site intracranial vessel occlusion . Patients randomize fingolimod also receive oral fingolimod ( Gilenya , Novartis ) dosage 0.5 mg daily , three consecutive day , first dose give time patient enrol one hour prior mechanical thrombectomy . The kinetics lymphocyte subset alteration monitor whole-blood sample fingolimod- treat patient baseline , precede first dose , day 1 day 7 . Mononuclear cell isolate whole-blood specimen stain antibody CD4-FITC , CD8-PE , CD19-PerCP , CD56-PE ( BD Biosciences , Franklin Lakes , NJ , USA ) . Data acquire use FACS Caliber ( Becton Dickinson Immunocytometry Systems , San Jose , CA , USA ) analyze Flow Jo software ( Tree Star , Ashland , OR , USA ) . The primary outcome salvage ischemic tissue ( ( baseline ischemic lesion - 7d infarction lesion ) / baseline ischemic lesion ) baseline day 7 . Secondary outcome growth infarct volume 24 hour DWI day 7 FLAIR imaging , penumbral salvage volume ( baseline hypoperfusion volume - 24-hours infarct volume ) baseline day 1 , frequency parenchymal hemorrhage ( PH ) day 1 extent clinical improvement day 1 measure change NIHSS score baseline day 1 , extent clinical improvement day 1 day 7 . The tertiary outcome probability excellent recovery day 90 ( mRS 0-1 ) , independent recovery ( mRS 0-2 ) ordinal analysis modify Rankin scale .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Patients present anterior circulation acute ischaemic stroke eligible alteplase mechanical thrombectomy commence within 6 hour stroke onset . 2 . Patient , family member legally responsible person depend local ethic requirement give informed consent . 3 . Patientâ€Ÿs age 1885 year . 4 . Arterial occlusion CTA ICA , M1 M2 . 5 . Imaging inclusion criterion : infarct core volume 15100 mL least 20 % mismatch ( evaluated CTP ) . 1 . Standard contraindication alteplase mechanical thrombectomy . 2 . Evidence diseases CNS . 3 . Preexisting neurologic disability ( score great 2 mRS ) . 4 . Swallowing difficulty would prevent administration oral fingolimod . 5 . Patients history bradyarrhythmia , atrioventricular block current use betablockers verapamil . 6 . Patients serious acute chronic infection , hepatic injury ( 3 time value normal ALS AST ) . 7 . Concomitant use antineoplastic , immunosuppressive immune modulate therapy . 8 . Macular edema .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Fingolimod Hydrochloride</keyword>
	<keyword>Intravenous thrombolysis</keyword>
	<keyword>Mechanical thrombectomy</keyword>
	<keyword>Acute ischemic stroke</keyword>
</DOC>